Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer

Mao Bin Meng, Huan Huan Wang, Nicholas G. Zaorsky, Xian Zhi Zhao, Zhi Qiang Wu, Bo Jiang, Yong Chun Song, Hong Qing Zhuang, Feng Tong Li, Lu Jun Zhao, Chang Li Wang, Kai Li, Ping Wang, Zhi Yong Yuan

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Aims: To evaluate the safety and efficacy of stereotactic radiotherapy (SRT, both stereotactic body RT [SBRT] and fractionated stereotactic RT [FSRT]) in the treatment of patients with recurrent or second primary mediastinal lymph node metastases (R/SP-MLNMs) originating from non-small cell lung cancer (NSCLC). Methods: Between 10/2006 and 7/2013, patients with R/SP-MLNMs originating from NSCLC were enrolled and treated with SRT at our hospital; their data was stored in prospectively-collected database. The enrolled patients were divided into Group A (without prior RT) and Group B (with prior RT). The primary end-point was overall survival (OS). The secondary end-points were the MLNM local control (LC), the time to symptom alleviation, and toxicity using the Common Terminology Criteria for Adverse Events (CTCAE v4.0). Results: Thirty-three patients were treated (16 in Group A with 19 R/SP-MLNMs and 17 in Group B with 17 R/SP-MLNMs). For the entire cohort, the median OS was 25.5 months with a median follow-up of 20.9 months (range, 3.2-82). The 1-year and 3-year actuarial LC rates were 100% and 86%, respectively. Symptom alleviation was observed in 52% of patients, after a median of 6 days (range, 3-18). CTCAE v4.0 = Grade 3 toxicities occurred in 5 patients (15%; all in Group B); among them, Grade 5 in 2 patients. Conclusions: We recommend exercising extreme caution in using SRT for R/SPMLNMs in patients who received prior RT (particularly to LN station 7). For patients without previous RT, SRT appears to be safe and efficacious treatment modality; prospective studies are warranted.

Original languageEnglish (US)
Pages (from-to)15690-15703
Number of pages14
JournalOncotarget
Volume6
Issue number17
DOIs
StatePublished - 2015

All Science Journal Classification (ASJC) codes

  • Oncology

Fingerprint Dive into the research topics of 'Clinical evaluation of stereotactic radiation therapy for recurrent or second primary mediastinal lymph node metastases originating from non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this